Pharmacovigilance in practice: erythropoiesis‐stimulating agents

Pharmacovigilance in practice: erythropoiesis-stimulating agents

Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other problems related to medical products after they have been licensed for marketing. The purpose of PV is to advance the safe use of marketed medical products. Regulatory agencies and license holders collaborate to collect data reported by health car...

Awareness, Attitude, and Practice of Pharmacovigilance among Health Care Professionals in Nigeria: Survey in a Teaching Hospital

Background and Objectives: Pharmacovigilance is central to the control of the menace of adverse drugs reactions. Despite the fact that development of policy and practice framework to improve patients’ safety partly rely on availability of authentic data on pharmacovigilance activities, knowledge about pharmacovigilance activities among healthcare professionals in Nigeria is limited. To help fil...

Good Pharmacovigilance Practice: Accountability of Ayurvedic Pharmaceutical Companies

© 2017 Ancient Science of Life | Published by Wolters Kluwer Medknow Sir, There is a paucity of systematic documentation apropos the occurrence of adverse drug reactions (ADRs) and other safety issues of Ayurveda medicines. National Pharmacovigilance program (NPP) for Ayurvedic drugs is concerned with re‐evaluation of marketed drugs, risk management, promoting rational drug use, and crisis prep...

a survey of knowledge, attitude and practice of nurses towards pharmacovigilance in teaching hospital, qazvin-iran

[Pharmacovigilance in clinical trials].

Prema definiciji Svetske zdravstvene organizacije farmakovigilanca je nauka ili skup aktivnosti povezanih sa detekcijom, procenom, razumevanjem i prevencijom neželjenih efekata ili bilo kojih drugih problema povezanih sa upotrebom lekova . Pod farmakovigilancom se, generalno, smatralo postmarketinško praćenje neželjenih efekata lekova u četvrtoj fazi kliničkih istraživanja lekova . Međutim, sa ...